The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

Globally, liver cancer is the most frequent fatal malignancy; in the United States, it ranks fifth.
Patients are often diagnosed with liver cancer in advanced stages, contributing to its poor …

BACKGROUND The efficacy and safety of transarterial chemoembolization (TACE) plus
lenvatinib in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus …

Hepatocellular carcinoma (HCC), the fifth most common cancer that predominantly occurs in
liver cirrhosis patients, requires staging systems to design treatments. The barcelona clinic …

Purpose To investigate the efficacy and safety of transarterial chemoembolization (TACE)
combined with lenvatinib plus PD-1 inhibitor (TACE-LP) versus TACE combined with …

The propensity score is defined as the probability of each individual study subject being
assigned to a group of interest for comparison purposes. Propensity score adjustment is a …

Background According to the 7th AJCC TNM staging system, solitary hepatocellular
carcinoma (HCC) is classified as T1 or T2 based on microvascular invasion (MVI) regardless …

Multiple systemic agents have recently been approved in the first-and second-line setting for
hepatocellular carcinoma (HCC), increasing the therapeutic options for patients and treating …

Background and Objectives This study aimed to compare the efficacy of transarterial
chemoembolization (TACE) plus sorafenib (TACE-S) to TACE plus lenvatinib (TACE-L) for …

Background This study investigated the survival benefits of sorafenib vs. radiotherapy (RT)
in patients with unresectable hepatocellular carcinoma (HCC) and portal vein tumor …